NLS Cash And Short Term Investments vs Long Term Debt Analysis
NLSP Stock | USD 0.16 0.01 6.67% |
NLS Pharmaceutics financial indicator trend analysis is infinitely more than just investigating NLS Pharmaceutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NLS Pharmaceutics is a good investment. Please check the relationship between NLS Pharmaceutics Cash And Short Term Investments and its Long Term Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
Cash And Short Term Investments vs Long Term Debt
Cash And Short Term Investments vs Long Term Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NLS Pharmaceutics Cash And Short Term Investments account and Long Term Debt. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between NLS Pharmaceutics' Cash And Short Term Investments and Long Term Debt is -0.14. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of NLS Pharmaceutics AG, assuming nothing else is changed. The correlation between historical values of NLS Pharmaceutics' Cash And Short Term Investments and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of NLS Pharmaceutics AG are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Cash And Short Term Investments i.e., NLS Pharmaceutics' Cash And Short Term Investments and Long Term Debt go up and down completely randomly.
Correlation Coefficient | -0.14 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Cash And Short Term Investments
Short Term Investments is an account in the current assets section of NLS Pharmaceutics balance sheet. This account contains NLS Pharmaceutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by NLS Pharmaceutics AG fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Long Term Debt
Long-term debt is a debt that NLS Pharmaceutics has held for over one year. Long-term debt appears on NLS Pharmaceutics AG balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on NLS Pharmaceutics AG balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.Most indicators from NLS Pharmaceutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NLS Pharmaceutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. At this time, NLS Pharmaceutics' Selling General Administrative is relatively stable compared to the past year. As of 05/23/2024, Enterprise Value is likely to grow to about 28.5 M, while Issuance Of Capital Stock is likely to drop 0.00.
NLS Pharmaceutics fundamental ratios Correlations
Click cells to compare fundamentals
NLS Pharmaceutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NLS Pharmaceutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 696.4K | 1.2M | 5.8M | 9.3M | 1.8M | 3.3M | |
Short Long Term Debt Total | 7.1M | 842.1K | 2.1M | 1.6M | 1.5M | 1.4M | |
Other Current Liab | 835.7K | (2.5B) | 666.4K | 986.4K | 1.7M | 1.7M | |
Total Current Liabilities | 4.0M | 7.2M | 2.4M | 3.4M | 7.9M | 4.5M | |
Total Stockholder Equity | (6.2M) | (9.0M) | 542.4K | 3.3M | (8.8M) | (9.3M) | |
Other Liab | 159.0K | 2.7M | 2.7M | 2.8M | 3.2M | 1.9M | |
Net Tangible Assets | (8.8M) | (6.2M) | (9.0M) | 542.4K | 623.7K | 654.9K | |
Net Debt | 621.9K | 2.0M | (5.4M) | (8.9M) | 736.1K | 772.9K | |
Retained Earnings | (26.9M) | (29.8M) | (41.7M) | (58.2M) | (70.4M) | (66.9M) | |
Accounts Payable | 2.5M | 4.0M | 1.7M | 2.4M | 4.6M | 2.7M | |
Cash | 220.3K | 93.7K | 5.4M | 8.9M | 897.7K | 852.8K | |
Non Current Assets Total | 314.7K | 1.0M | 41.6K | 30.2K | 23.6K | 22.4K | |
Non Currrent Assets Other | 260.2K | 946.9K | 12.0K | 12.1K | 16.9K | 16.0K | |
Cash And Short Term Investments | 220.3K | 93.7K | 5.4M | 8.9M | 897.7K | 852.8K | |
Net Receivables | 75.4K | 61.2K | 38.6K | 41.2K | 10.7K | 10.1K | |
Common Stock Shares Outstanding | 11.1M | 4.8M | 14.7M | 19.7M | 38.2M | 40.1M | |
Liabilities And Stockholders Equity | 696.4K | 1.2M | 5.8M | 9.3M | 1.8M | 3.3M | |
Non Current Liabilities Total | 2.8M | 3.0M | 2.8M | 2.6M | 2.8M | 3.4M | |
Other Current Assets | 86.1K | 103K | 292.0K | 298.0K | 914.7K | 960.5K | |
Other Stockholder Equity | 20.6M | 20.6M | 42.1M | 60.9M | 61.0M | 35.5M | |
Total Liab | 6.9M | 10.2M | 5.2M | 6.0M | 10.7M | 6.6M | |
Net Invested Capital | (5.3M) | (6.9M) | 542.4K | 3.3M | (7.2M) | (6.8M) | |
Total Current Assets | 381.7K | 196.7K | 5.7M | 9.2M | 1.8M | 3.1M | |
Accumulated Other Comprehensive Income | (18.7K) | (19.4K) | (151.7K) | (50.8K) | (158.1K) | (150.2K) | |
Net Working Capital | (3.7M) | (7.0M) | 3.3M | 5.9M | (6.1M) | (5.8M) | |
Inventory | (33.6K) | (61.2K) | (38.6K) | (41.2K) | (37.1K) | (39.0K) | |
Short Term Debt | 690.1K | 1.8M | 2.5B | 1.6M | 1.9M | 1.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for NLS Stock analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is NLS Pharmaceutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NLS Pharmaceutics. If investors know NLS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NLS Pharmaceutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.32) | Return On Assets (1.33) | Return On Equity (8.63) |
The market value of NLS Pharmaceutics is measured differently than its book value, which is the value of NLS that is recorded on the company's balance sheet. Investors also form their own opinion of NLS Pharmaceutics' value that differs from its market value or its book value, called intrinsic value, which is NLS Pharmaceutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NLS Pharmaceutics' market value can be influenced by many factors that don't directly affect NLS Pharmaceutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NLS Pharmaceutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NLS Pharmaceutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NLS Pharmaceutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.